XTL Biopharmaceuticals Ltd. (ADR)
General ticker "XTLB" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $7.9M (TTM average)
XTL Biopharmaceuticals Ltd. (ADR) does not follow the US Stock Market performance with the rate: -3.1%.
Estimated limits based on current volatility of 4.1%: low 0.82$, high 0.89$
Factors to consider:
- Total employees count: 42 as of 2005
- Current price 22.7% below estimated low
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.13$, 2.77$]
- 2025-12-31 to 2026-12-31 estimated range: [0.94$, 2.40$]
Financial Metrics affecting the XTLB estimates:
- Positive: with PPE of -12.8 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -13.45 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: Inventory ratio change, % of -3.84 <= -0.75
- Positive: Shareholder equity ratio, % of 63.57 > 63.39
- Negative: 0.01 < Interest expense per share per price, % of 0.71
Short-term XTLB quotes
Long-term XTLB plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.45MM |
| Operating Expenses | $0.88MM | $0.77MM | $2.62MM |
| Operating Income | $-0.88MM | $-0.77MM | $-2.17MM |
| Non-Operating Income | $-0.47MM | $-1.02MM | $1.01MM |
| Interest Expense | $0.01MM | $0.00MM | $0.09MM |
| R&D Expense | $0.03MM | $0.03MM | $0.10MM |
| Income(Loss) | $-1.35MM | $-1.78MM | $-1.16MM |
| Taxes | $0.00MM | $-0.00MM | $-0.13MM |
| Profit(Loss)* | $-1.35MM | $-0.00MM | $-1.03MM |
| Stockholders Equity | $4.00MM | $2.22MM | $5.43MM |
| Assets | $4.19MM | $2.43MM | $8.55MM |
| Operating Cash Flow | $-0.90MM | $-0.71MM | $-1.62MM |
| Capital expenditure | $0.00MM | $0.00MM | $0.05MM |
| Investing Cash Flow | $0.04MM | $0.04MM | $-0.84MM |
| Financing Cash Flow | $0.00MM | $0.00MM | $1.45MM |
| Earnings Per Share** | $-0.25 | $-0.00 | $-0.15 |
| Ordinary share to ADR | 0.01x | 0.01x | 0.01x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.